A Clinical Guide to Using Cannabinoid Therapies for Cancer Patients at Every Stage of Disease
A practical guide for oncology clinicians details how cannabinoid therapies (pharmaceutical, botanical, and edible) can address pain, nausea, and appetite loss in cancer patients while potentially reducing overall polypharmacy.
Quick Facts
What This Study Found
This review provides a clinical roadmap for using cannabinoid therapies in cancer care. Patients with malignant disease have among the greatest unmet symptom management needs despite available treatments.
Cannabinoids offer a versatile toolkit. Pharmaceutical options include nabilone, dronabinol, and nabiximols (Sativex). Patients can also access dried botanical cannabis and edible oils. Treatment regimens can creatively combine these modalities.
The most established evidence supports cannabinoids for cancer-related pain, chemotherapy-induced nausea and vomiting, and anorexia/cachexia. A key advantage highlighted is cannabinoids' ability to address multiple symptoms simultaneously, potentially reducing the number of other medications needed (polypharmacy).
The authors argue that cannabinoid therapy could benefit cancer patients at all disease stages, from active treatment through palliative care, either as standalone treatment or as an adjunct to conventional therapies.
Key Numbers
Three pharmaceutical cannabinoids reviewed: nabilone, dronabinol, nabiximols. Three primary evidence-based indications: pain, chemotherapy-induced nausea/vomiting, anorexia. Multiple formulation options: pharmaceuticals, dried botanical, edible oils.
How They Did This
Clinical review and practical guide addressing available cannabinoid formulations, evidence-based indications, dosing considerations, and integration strategies for oncology practice.
Why This Research Matters
Cancer patients often take numerous medications for different symptoms. Cannabinoids' ability to simultaneously address pain, nausea, and appetite loss could simplify treatment regimens while improving quality of life, potentially also improving compliance with cancer-directed therapies like chemotherapy.
The Bigger Picture
This review reflects a shift in oncology toward viewing cannabinoids as legitimate therapeutic tools rather than alternative medicines. The practical, clinician-focused approach suggests growing acceptance of cannabinoid integration into standard cancer care.
What This Study Doesn't Tell Us
Much of the evidence for cannabinoids in cancer comes from small trials. The anti-tumor potential mentioned is mostly preclinical. Individual patient responses to cannabinoids vary widely. Drug interactions with cancer therapies need more study.
Questions This Raises
- ?Which cancer patients benefit most from cannabinoid therapy?
- ?Can cannabinoids improve chemotherapy adherence by reducing side effects?
- ?Do cannabinoids have direct anti-cancer effects in humans?
Trust & Context
- Key Stat:
- Cannabinoids can address multiple cancer symptoms simultaneously, reducing polypharmacy
- Evidence Grade:
- Clinical review providing practical guidance based on available evidence. Well-established for some indications (nausea), less so for others.
- Study Age:
- Published in 2016. Evidence for cannabinoids in cancer symptom management has continued to accumulate.
- Original Title:
- A user's guide to cannabinoid therapies in oncology.
- Published In:
- Current oncology (Toronto, Ont.), 23(6), 398-406 (2016)
- Authors:
- Maida, V, Daeninck, P J
- Database ID:
- RTHC-01221
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Which cancer symptoms can cannabinoids help with?
The strongest evidence supports cannabinoids for cancer pain, chemotherapy-induced nausea and vomiting, and loss of appetite/weight. A key advantage is treating multiple symptoms with one therapy instead of several medications.
What forms of cannabinoid therapy are available for cancer patients?
Options include pharmaceutical products (nabilone, dronabinol, Sativex), dried botanical cannabis, and edible cannabis oils. Treatment regimens can combine different modalities based on patient needs.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-01221APA
Maida, V; Daeninck, P J. (2016). A user's guide to cannabinoid therapies in oncology.. Current oncology (Toronto, Ont.), 23(6), 398-406. https://doi.org/10.3747/co.23.3487
MLA
Maida, V, et al. "A user's guide to cannabinoid therapies in oncology.." Current oncology (Toronto, 2016. https://doi.org/10.3747/co.23.3487
RethinkTHC
RethinkTHC Research Database. "A user's guide to cannabinoid therapies in oncology." RTHC-01221. Retrieved from https://rethinkthc.com/research/maida-2016-a-users-guide-to
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.